Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Cullinan Therapeutics Inc (NQ: CGEM ) 15.78 +0.23 (+1.48%) Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Cullinan Therapeutics Inc < Previous 1 2 3 4 5 Next > Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus October 16, 2024 From Cullinan Therapeutics, Inc. Via GlobeNewswire Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market September 25, 2024 Amgen reports mixed results from Phase 3 trials, with rocatinlimab showing moderate success in atopic dermatitis and Uplizna outperforming expectations in myasthenia gravis, offering less frequent... Via Benzinga Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus September 17, 2024 From Cullinan Therapeutics, Inc. Via GlobeNewswire Cullinan Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus Erythematosus September 16, 2024 From Cullinan Therapeutics, Inc. Via GlobeNewswire Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024 September 14, 2024 From Cullinan Therapeutics, Inc. Via GlobeNewswire Cullinan Therapeutics to Participate in Upcoming Investor Conferences August 28, 2024 From Cullinan Therapeutics, Inc. Via GlobeNewswire Merck's $1.3B Deal For Potential Autoimmune Disorder Candidate Is Relevant To Cullinan's Investigational Drug, Says Analyst August 09, 2024 Merck has agreed to acquire CN201, a bispecific antibody from Curon Biopharmaceutical, for $700 million. This acquisition aims to advance Merck's pipeline for treating B-cell malignancies and... Via Benzinga CGEM Stock Earnings: Cullinan Therapeutics Misses EPS for Q2 2024 August 08, 2024 CGEM stock results show that Cullinan Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. Via InvestorPlace Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results August 08, 2024 From Cullinan Therapeutics, Inc. Via GlobeNewswire Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib June 01, 2024 Objective response rate of 39% with manageable safety profile in patients with non-small cell lung cancer (NSCLC) harboring EGFR Exon 20 insertion mutations treated with zipalertinib who had progressed... From Cullinan Therapeutics, Inc. Via GlobeNewswire Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit May 24, 2024 From Cullinan Therapeutics, Inc. Via GlobeNewswire Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024 May 23, 2024 From Cullinan Therapeutics, Inc. Via GlobeNewswire CGEM Stock Earnings: Cullinan Oncology Beats EPS for Q1 2024 May 15, 2024 CGEM stock results show that Cullinan Oncology beat analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results May 15, 2024 From Cullinan Therapeutics, Inc. Via GlobeNewswire Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session April 29, 2024 Via Benzinga Tesla, Deciphera Pharmaceuticals, Heartland Financial And Other Big Stocks Moving Higher On Monday April 29, 2024 Via Benzinga Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer April 29, 2024 From Cullinan Therapeutics, Inc. Via GlobeNewswire Why Aon Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session April 26, 2024 Via Benzinga 12 Health Care Stocks Moving In Friday's Intraday Session April 26, 2024 Via Benzinga Skechers Reports Upbeat Earnings, Joins Tutor Perini, AppFolio, Newell Brands And Other Big Stocks Moving Higher On Friday April 26, 2024 Via Benzinga Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday? April 24, 2024 Explore the use of Amgen's Blincyto in treating severe systemic sclerosis, shedding light on Cullinan Therapeutics' CLN-978 potential for autoimmune diseases, particularly systemic lupus... Via Benzinga Hilton Worldwide Reports Upbeat Results, Joins Hasbro, Vertiv Holdings And Other Big Stocks Moving Higher On Wednesday April 24, 2024 Via Benzinga Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024 April 24, 2024 From Cullinan Therapeutics, Inc. Via GlobeNewswire United Airlines Reports Upbeat Results, Joins Children's Place, Interactive Brokers And Other Big Stocks Moving Higher On Wednesday April 17, 2024 U.S. stocks were lower, with the Dow Jones index falling over 50 points on Wednesday. Via Benzinga Topics Stocks Exposures US Equities Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session April 17, 2024 Shares of The Travelers Companies, Inc. (NYSE: TRV) fell sharply during Wednesday’s session following first-quarter earnings. Via Benzinga Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session April 16, 2024 Shares of Skillsoft Corp. (NASDAQ: SKIL) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial results and issued FY25 revenue guidance below estimates. Via Benzinga Cullinan Shifts Focus From Oncology To Autoimmune Disorders, Raises $280M Via Equity April 16, 2024 Cullinan shifts focus to autoimmune diseases with CLN-978, targeting systemic lupus erythematosus. Initial trial results show potential for treatment with a differentiated safety profile. Via Benzinga UnitedHealth Reports Upbeat Earnings, Joins Cullinan Oncology, Ericsson And Other Big Stocks Moving Higher On Tuesday April 16, 2024 U.S. stocks were mostly higher, with the Dow Jones index gaining over 100 points on Tuesday. Via Benzinga Topics Stocks Exposures US Equities Cullinan Management Inc. (NASDAQ: CGEM) Records 52-Week High Tuesday Morning April 16, 2024 Via Investor Brand Network 12 Health Care Stocks Moving In Tuesday's Pre-Market Session April 16, 2024 Via Benzinga < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
